Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles

References

• Zell R, Delwart E, Gorbalenya AE, et al. ICTV virus taxonomy profile: picornaviridae. J Gen Virol. 2017 Oct;98(10):2421–2422. doi:10.1099/jgv.0.000911
   PubMed Web of Science ®Google Scholar
• Yoon JW, Austin M, Onodera T, et al. Virus-Induced Diabetes-Mellitus - Isolation of a Virus from the Pancreas of a Child Withdiabetic Ketoacidosis. New Engl J Med. 1979;300(21):1173–1179. doi:10.1056/NEJM197905243002102
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang Y, Gu S, et al. New coxsackievirus B4 genotype circulating in Inner Mongolia autonomous region, China. PLoS One. 2014;9(3):e90379, doi:10.1371/journal.pone.0090379
   PubMed Web of Science ®Google Scholar
• Yoon JW, Austin M, Onodera T, et al. Virus-Induced diabetes mellitus-Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med. 1979 May 24;300(21):1173–1179. doi:10.1056/NEJM197905243002102
   PubMed Web of Science ®Google Scholar
• Mulders MN, Salminen M, Kalkkinen N, et al. Molecular epidemiology of coxsackievirus B4 and disclosure of the correct VP1/2Apro cleavage site: evidence for high genomic diversity and long-term endemicity of distinct genotypes. J Gen Virol. 2000 Mar;81(Pt 3):803–812. doi:10.1099/0022-1317-81-3-803
   PubMedGoogle Scholar
• Xiao J, Wang J, Zhang Y, et al. Coxsackievirus B4: an underestimated pathogen associated with a hand, foot, and mouth disease outbreak. Arch Virol. 2021 Aug;166(8):2235–2247. doi:10.1007/s00705-021-05125-8
   PubMed Web of Science ®Google Scholar
• Xiao J, Wang J, Lu H, et al. Genomic epidemiology and transmission dynamics of global coxsackievirus B4. Viruses. 2023 Feb 19;15(2.
   Web of Science ®Google Scholar
• Tan EL, Wong AP, Poh CL. Development of potential antiviral strategy against coxsackievirus B4. Virus Res. 2010 Jun;150(1-2):85–92. doi:10.1016/j.virusres.2010.02.017
   PubMed Web of Science ®Google Scholar
• Khetsuriani N, Lamonte-Fowlkes A, Oberst S, et al. Enterovirus surveillance–United States, 1970-2005. MMWR Surveill Summ. 2006 Sep 15;55(8):1–20.
   PubMedGoogle Scholar
• Ikeda T, Saito T, Takagi G, et al. Acute myocarditis associated With coxsackievirus B4 mimicking influenza myocarditis. Circulation. 2013 Dec 24;128(25):2811–2812. doi:10.1161/CIRCULATIONAHA.112.000602
   PubMed Web of Science ®Google Scholar
• Cree BC, Bernardini GL, Hays AP, et al. A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol. 2003 Jan;60(1):107–112. doi:10.1001/archneur.60.1.107
   PubMedGoogle Scholar
• Hu YF, Du J, Zhao R, et al. Complete genome sequence of a recombinant coxsackievirus B4 from a patient with a fatal case of hand, foot, and mouth disease in Guangxi, China. J Virol. 2012 Oct;86(19):10901–2. doi:10.1128/JVI.01808-12
   PubMed Web of Science ®Google Scholar
• Bissel SJ, Winkler CC, DelTondo J, et al. Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathology. 2014 Oct;34(5):429–437. doi:10.1111/neup.12121
   PubMed Web of Science ®Google Scholar
• Cho SM, MacDonald S, Frontera JA. Coxsackie B3/B4-related acute flaccid myelitis. Neurocrit Care. 2017 Oct;27(2):259–260. doi:10.1007/s12028-017-0377-8
   PubMed Web of Science ®Google Scholar
• Lampropoulos K, Bazoukis G, Kolyviras A, et al. Pancreatitis and myocarditis coexistence due to infection by Coxsackie B1 and B4 viruses. Clin Case Rep. 2018 Jan;6(1):23–26. doi:10.1002/ccr3.1277
   PubMedGoogle Scholar
• Nihalani KD, Pethani RR, Menon PS, et al. Coxsackie B4 virus causing insulin dependent diabetes mellitus, myopericarditis and encephalitis–a case report. J Assoc Physicians India. 1982 Feb;30(2):107–109.
   PubMedGoogle Scholar
• Taraszkiewicz F, Oldak E, Slizewska T, et al. A case of encephalitis of mixed Coxsackievirus B4 and rubella viral etiology in a 9-year old boy. Pol Merkur Lekarski. 1996 Dec;1(6):417–418.
   PubMedGoogle Scholar
• Lee CJ, Huang YC, Yang S, et al. Clinical features of coxsackievirus A4, B3 and B4 infections in children. PLoS One. 2014;9(2):e87391, doi:10.1371/journal.pone.0087391
   PubMed Web of Science ®Google Scholar
• Le Van Quyen P, Desprez P, Livolsi A, et al. Peculiar clinical presentation of coxsackievirus B4 infection: neonatal restrictive cardiomyopathy. AJP Rep. 2017 Apr;07(2):e124–e126. doi:10.1055/s-0037-1601352
   Google Scholar
• Ji-Won Yoon MA, Onodera T, Notkins AL. Virus-induced diabetes mellitus — isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med. 1979;300:1173–1179. doi:10.1056/NEJM197905243002102
   PubMed Web of Science ®Google Scholar
• Badia-Boungou F, Sane F, Alidjinou EK, et al. Marker of coxsackievirus-B4 infection in saliva of patients with type 1 diabetes. Diabetes-Metab Res. 2017 Oct;33(7).
   PubMed Web of Science ®Google Scholar
• Chehadeh W, Kerr-Conte J, Pattou F, et al. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in β cells. J Virol 2000 Nov;74(21):10153–10164. doi:10.1128/JVI.74.21.10153-10164.2000
   PubMed Web of Science ®Google Scholar
• Jaïdane H, Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. 2008 Dec;34(6):537–548. doi:10.1016/j.diabet.2008.05.008
   PubMed Web of Science ®Google Scholar
• Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet. 1995 Jul 22;346(8969):221–223. doi:10.1016/S0140-6736(95)91270-3
   PubMed Web of Science ®Google Scholar
• Dotta F, Censini S, van Halteren AGS, et al. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. P Natl Acad Sci USA. 2007 Mar 20;104(12):5115–5120. doi:10.1073/pnas.0700442104
   PubMed Web of Science ®Google Scholar
• Walter DL, Benner SE, Oaks RJ, et al. Coxsackievirus B4 exposure results in variable pattern recognition response in the kidneys of female Non-obese diabetic mice before establishment of diabetes. Viral Immunol. 2020 Sep 1;33(7):494–506. doi:10.1089/vim.2019.0188
   PubMed Web of Science ®Google Scholar
• Nekoua MP, Bertin A, Sane F, et al. Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity. Cell Mol Life Sci. 2020 Jan;77(1):179–194. doi:10.1007/s00018-019-03168-4
   PubMed Web of Science ®Google Scholar
• Benner SE, Walter DL, Thuma JR, et al. Toll-Like receptor 3 Is critical to the pancreatic islet milieu that Is required for coxsackievirus B4-induced type 1 diabetes in female nonobese diabetic mice. Pancreas. 2022 Jan;51(1):48–55. doi:10.1097/MPA.0000000000001960
   PubMed Web of Science ®Google Scholar
• Dai J, Xu D, Yang C, et al. Severe pneumonia and pathogenic damage in human airway epithelium caused by Coxsackievirus B4. Emerg Microbes Infect. 2023 Dec;12(2):2261560, doi:10.1080/22221751.2023.2261560
   PubMed Web of Science ®Google Scholar
• Ray CG, Plexico KL, Wenner HA, et al. Acute respiratory illness associated with coxsackie B4 virus in children. Pediatrics. 1967;39(2):220, doi:10.1542/peds.39.2.220
   PubMed Web of Science ®Google Scholar
• Hierholzer JC, Mostow SR, Dowdle WR. Prospective study of a mixed coxsackie virus B3 and B4 outbreak of upper respiratory illness in a children's home. Pediatrics. 1972 May;49(5):744–752. doi:10.1542/peds.49.5.744
   PubMed Web of Science ®Google Scholar
• Chien YS, Luo ST, Tsao KC, et al. Genomic analysis of serologically untypable human enteroviruses in Taiwan. J Biomed Sci. 2019 Jul 3;26(1):49, doi:10.1186/s12929-019-0541-x
   PubMedGoogle Scholar
• Liu Y, Chen J, Zhang M, et al. Coxsackievirus B: the important agent of hand, foot, and mouth disease. J Med Virol. 2023 Mar;95(3):e28669, doi:10.1002/jmv.28669
   PubMed Web of Science ®Google Scholar
• Tan ZL, Lyu LK, Xie T, et al. An imported genotype D coxsackievirus B4 strain identified in Tianjin, China. Biomed Environ Sci. 2022 Mar 20;35(3):239–247.
   PubMed Web of Science ®Google Scholar
• Jenkins O, Booth JD, Minor PD, et al. The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. J Gen Virol. 1987 Jul;68(Pt 7):1835–1848. doi:10.1099/0022-1317-68-7-1835
   PubMedGoogle Scholar
• Jiang P, Liu Y, Ma HC, et al. Picornavirus morphogenesis. Microbiol Mol Biol R. 2014 Sep;78(3):418–437. doi:10.1128/MMBR.00012-14
   PubMed Web of Science ®Google Scholar
• Flatt JW, Domanska A, Seppala AL, et al. Identification of a conserved virion-stabilizing network inside the interprotomer pocket of enteroviruses. Commun Biol. 2021 Feb 26;4(1):250, doi:10.1038/s42003-021-01779-x
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808. doi:10.2217/fmb.15.19
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016 May;15(5):599–606. doi:10.1586/14760584.2016.1138862
   PubMed Web of Science ®Google Scholar
• Hummeler K, Hamparian VV. Studies on the complement fixing antigens of poliomyelitis. I. Demonstration of type and group specific antigens in native and heated viral preparations. J Immunol. 1958 Dec;81(6):499–505. doi:10.4049/jimmunol.81.6.499
   PubMed Web of Science ®Google Scholar
• Mayer MM, Rapp HJ, Roizman B, et al. The purification of poliomyelitis virus as studied by complement fixation. J Immunol. 1957;78(6):435–455. doi:10.4049/jimmunol.78.6.435
   PubMed Web of Science ®Google Scholar
• Hummeler K, Brown RA, Anderson TF. Identification of poliovirus particles of different antigenicity by specific agglutination as seen in the electron microscope. Virology. 1962;16(1):84, doi:10.1016/0042-6822(62)90205-2
   PubMed Web of Science ®Google Scholar
• Schwerdt CE, Fogh J. The ratio of physical particles Per infectious unit observed for poliomyelitis viruses. Virology. 1957;4(1):41–52. doi:10.1016/0042-6822(57)90042-9
   PubMed Web of Science ®Google Scholar
• Lebouvier GL. The modification of poliovirus antigens by heat and ultraviolet light. Lancet. 1955;2(Nov12):1013–1016.
   Web of Science ®Google Scholar
• Singer C, Knauert F, Bushar G, et al. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand. 1989;17(2):137–150. doi:10.1016/0092-1157(89)90004-8
   PubMedGoogle Scholar
• Chong P, Guo MS, Lin FHY, et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One. 2012 Nov 30;7(11.
   Web of Science ®Google Scholar
• Liu QW, Ku ZQ, Cai YC, et al. Detection, characterization and quantitation of Coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods. 2011 Apr;173(1):115–120. doi:10.1016/j.jviromet.2011.01.016
   PubMed Web of Science ®Google Scholar
• Mone K, Lasrado N, Sur M, et al. Vaccines against group B coxsackieviruses and their importance. Vaccines-Basel. 2023 Feb;11(2.
   PubMed Web of Science ®Google Scholar
• Davydova B, Härkönen T, Kaialainen S, et al. Coxsackievirus immunization delays onset of diabetes in non-obese diabetic mice. J Med Virol. 2003 Apr;69(4):510–520. doi:10.1002/jmv.10339
   PubMed Web of Science ®Google Scholar
• Stone VM, Hankaniemi MM, Laitinen OH, et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 2020 May;6(19.
   Web of Science ®Google Scholar
• Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines. 2018;17(9):819–831. doi:10.1080/14760584.2018.1510326
   PubMed Web of Science ®Google Scholar
• Ku ZQ, Ye XH, Huang XL, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at Pre- and post-attachment steps. PLoS One. 2013 Feb 22;8(2.
   Web of Science ®Google Scholar
• Liu QW, Yan KX, Feng YF, et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012 Oct 19;30(47):6642–6648. doi:10.1016/j.vaccine.2012.08.071
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shen CY, Zhang C, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antivir Res. 2016 Aug;132:165–169. doi:10.1016/j.antiviral.2016.06.004
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang C, Liu QW, et al. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antivir Res. 2018 Apr;;152:124–130. doi:10.1016/j.antiviral.2018.02.016
   PubMed Web of Science ®Google Scholar
• Gharbi J, Hassine IH, Hassine M, et al. Viral protein VP1 virus-like particles (VLP) of CVB4 induces protective immunity against lethal challenges with diabetogenic E2 and wild type JBV strains in mice model. Viruses-Basel. 2023 Apr;15(4).
   PubMed Web of Science ®Google Scholar